Chronic hepatitis B virus (HBV) infection is an international health problem with extremely
high mortality and morbidity rates. Although current clinical chronic hepatitis B (CHB) …

Hepatitis B virus (HBV) infection is a major public health problem worldwide. HBV is not
directly cytotoxic to infected hepatocytes; the clinical outcome of infection results from …

Hepatitis B virus (HBV) infection is still a worldwide health problem; however, the current
antiviral therapies for chronic hepatitis B are limited in efficacy. The outcome of HBV …

Chronic hepatitis B virus (HBV) infection is a major global public health risk that threatens
human life and health, although the number of vaccinated people has increased. The …

Approximately 400 million people are chronically infected with hepatitis B virus (HBV)
globally despite the widespread immunization of HBV vaccine and the development of …

Abstract Treatment of chronic hepatitis B virus (HBV) infection with the viral DNA polymerase
inhibitors or pegylated alpha-interferon has led to a significant retardation in HBV-related …

Chronic hepatitis B virus (HBV) infection remains a major cause of morbidity and mortality
worldwide. HBV surface antigen loss is considered a functional cure and is an ideal goal for …

Chronic hepatitis B infection remains a major disease burden globally, and leads to high risk
of hepatocellular carcinoma development. Current therapies of nucleot (s) ide analogues …

Hepatitis B virus (HBV) causes chronic infections that are associated with immune
dysfunction. Though T cell impairment is perhaps the most prominent immune change …

Highlights•HBV evades, subverts, activates and regulates various host immune components
upon infection.•Immune concepts and terminologies in clinical CHB phenotypes need re …